Fund Manager Summary on Sigma Healthcare Ltd (ASX:SIG)
Sigma Healthcare Ltd (ASX: SIG) is positioned for robust growth following its merger with Chemist Warehouse, which now represents over 90% of its value. Recent commentary emphasizes significant operational leverage and international expansion potential, particularly in Ireland and New Zealand, as Chemist Warehouse adapts its successful business model. The company reported a 41% increase in underlying earnings for FY25, supported by aggressive new store openings and upgraded cost savings targets of $100 million. However, risks include share price volatility amid market adjustments and the necessity to maintain operational excellence during integration. Investors are encouraged by the expected tailwinds from an aging population and market share gains, particularly in emerging pharmaceutical segments such as GLP-1 medications. Overall, Sigma's leading position and strategic initiatives suggest a positive outlook, contingent on effective execution and market adaptation.
Commentary From The Managers
There are 21 insights from 9 fund managers regarding their investment in Sigma Healthcare Ltd (ASX:SIG) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
Hyperion Asset Management
28 Feb 2026
$2.75
Summary
- Hyperion Asset Management believes Sigma Healthcare (Chemist Warehouse) is a structurally advantaged retail health operator and continues to hold, backed by compelling like-for-like sales growth, expanding store networks, and growing cost synergies.
- Sigma delivered a strong 1H FY26 result, with group sales up 14.9%, driven by Chemist Warehouse network sales growth of 17.2% in Australia and 24.5% internationally.
- Like-for-like sales growth was outstanding: +15.0% in Australia and +11.1% internationally, materially outpacing the broader market.
- Early 2H FY26 trading remains strong, with year-to-date sales +16.6% and LFL +14.4% (inclusive of the first 7 weeks of 2H FY26).
- Group EBIT rose 18.7% with margin expansion of 34bps, driven by scale benefits and distribution and supplier efficiencies.
- Chemist Warehouse opened 13 new Australian stores in 1H FY26 (targeting +9 in 2H) and 12 internationally (targeting +11 in 2H), implying significant continued store rollout potential toward long-term targets of 900 Australian CW stores, 300 Amcal, and 150 Discount Drug Stores.
- The group is on track to achieve $100m p.a. in cost synergies by FY29, with distribution costs flat in 1H despite unit volume growth of 5.1%.
- Industry data supports a structural channel shift from supermarkets to Chemist Warehouse in pharmaceuticals, cosmetics, and toiletries, underpinning durable market share gains.
Antares Capital
31 Oct 2025
$3.11
Summary
- Antares Capital is attracted to the various tailwinds for Sigma Healthcare Ltd, particularly the aging population.
- The fund manager recognizes a growing consumer focus on well-being.
- Antares Capital was seeking an entry point due to the elevated trading multiple.
- Having studied Sigma's expansion in the New Zealand market, the fund manager sees potential where many Australian retailers have struggled.
- The Chemist Warehouse model is viewed as replicable in countries with similar pharmacy retail regulations.
- Antares Capital believes there is a long growth runway for Sigma Healthcare Ltd, justifying the elevated multiple.
ELM Responsible Investments
31 Oct 2025
$3.11
Summary
- Sigma Healthcare exhibited strong momentum in Q1 FY26 post-merger with Chemist Warehouse Group.
- Total Chemist Warehouse Network sales growth of 17.9%, and like-for-like sales increased by 14.7%.
- Integration progress is ahead of expectations, with management upgrading annual synergy benefits from $60 million to $100 million by year four.
- First AGM as a merged entity held in October, showcasing strong performance across key product categories.
- Strong contribution from GLP-1 weight loss drugs like Ozempic.
- Sigma is actively expanding new stores domestically and internationally to achieve network growth.
- Focus on expanding exclusive and own-brand product ranges to enhance margins and differentiation.
- Market capitalisation nearing $35 billion, placing Sigma in the ASX top 20.
- Positioned well for sustained growth as it leverages scale as a leading retail pharmacy franchisor and pharmaceutical wholesaler.
Pendal Group
27 Oct 2025
$3.08
Summary
- Pendal Group notes strong 1Q26 sales for Sigma Healthcare.
- Chemist Warehouse reported 14.7% growth in like-for-like sales, exceeding market growth rates.
- Availability of GLP-1 anti-obesity treatments identified as a significant sales growth tailwind.
- Continued strong trading supports an elevated valuation.
- Update led to consensus upgrades of 2-3% for FY26.
Hyperion Asset Management
30 Sept 2025
$2.97
Summary
- Positive FY25 result for Sigma Healthcare Ltd following Chemist Warehouse acquisition completion.
- Group pro-forma revenue increased by 44% and EBIT by 49%, driven by Chemist Warehouse sales growth.
- Strong Chemist Warehouse network sales growth with 14% increase in FY25, significantly outpacing the market.
- Industry-leading like-for-like sales growth of 11% in Australia and 8% internationally.
- Double-digit LFL momentum continued into the first two months of FY26.
- Structural channel shift from supermarkets to Chemist Warehouse in pharmaceuticals, cosmetics, and toiletries.
- Store rollout in FY25 included 19 new stores in Australia and 16 internationally, showcasing model scalability.
- Upgraded cost synergy targets to $100m p.a. in four years, with evidence of operating leverage.
- Chemist Warehouse as a 'category killer' with significant growth potential in Australia and internationally.
- Positioned for sustained double-digit growth and continued market share gains.
Ten Cap
31 Aug 2025
$3.13
Summary
- Ten Cap continues to hold Sigma Healthcare (SIG) due to operational progress supporting an earnings recovery.
- Improving execution and scale benefits are seen as key factors in underpinning a multi-year margin rebuild.
- There is potential for upside as the operating environment normalizes.
- Continued investment reflects confidence in SIG's operating leverage.
ELM Responsible Investments
31 Aug 2025
$3.13
Summary
- ELM Responsible Investments notes Sigma Healthcare's strong FY25 performance post-merger with Chemist Warehouse Group.
- Reported a 41% increase in underlying earnings to $835 million.
- Net profit rose 40% to $579 million.
- Revenue surged 82%, showcasing the benefits of the combined group's scale.
- Chemist Warehouse achieved 14% growth in retail sales and opened 35 new stores.
- Management increased expected cost savings from $60 million to $100 million.
- Cost efficiencies from higher distribution volumes led to a 11% reduction in logistics costs.
- Sigma is focused on consolidating its physical store network in China while expanding online sales.
- Streamlining distribution is key to sustaining growth and profitability.
Airlie Funds Management
30 June 2025
$2.99
Summary
- Sigma Healthcare Ltd is a major Australian pharmaceutical wholesale and distribution company.
- It has merged with the Chemist Warehouse Group and includes well-known retail brands such as Amcal, Guardian, PharmaSave, and Discount Drug Stores.
- Sigma provides essential services to community pharmacies, including wholesale distribution and third-party logistics solutions.
- Sigma was the Fund’s strongest contributor during the year, with a contribution of +4.8% to gross performance.
- Airlie Funds Management first purchased Sigma in December 2023, anticipating the merger with Chemist Warehouse would proceed despite potential regulatory risks.
- The decision was based on a belief that the return was asymmetric given the merger's potential benefits.
- Airlie Funds Management kept the initial position size relatively small due to the inherent risks involved.
- Chemist Warehouse exemplifies the type of business Airlie Funds Management aims to own, characterized by a durable competitive advantage.
- The company has a fantastic founder-led management team and a strong balance sheet.
- There is a long runway to reinvest capital both internationally and within its core Australian market.
- For further details, refer to the September 2024 Quarterly Commentary available on the Airlie website.
Cooper Investors
30 June 2025
$2.99
Summary
- SIG achieved a significant milestone with the ACCC’s approval of its reverse merger with Chemist Warehouse (CWH), which now constitutes over 90% of SIG’s value.
- CWH is a dominant force in the retail pharmacy sector, recognized as a true "category killer".
- Exceptional long-term growth outlook for CWH, driven by market share gains in Australia and New Zealand and international store expansion.
- CWH excels in store productivity, significantly outpacing major supermarkets with exceptional store economics.
- Management team boasts a 50+ year track record of successful store rollouts and organic sales growth.
- Attractive business model characterized by a commitment to offering the lowest prices, akin to successful operators like Costco and Aldi.
- Chemist Warehouse has expanded to over 500 stores in Australia, 60 in New Zealand, and has international presence in China, Ireland, and Dubai.
- Future value identified despite SIG’s share price response, driven by exceptional management under CEO Mario Verrocchi.
- Opportunities for growth as CWH expands internationally, dominates the New Zealand market, and captures market share from supermarkets.
- Potential high-margin growth from retail media and above-expected merger synergies.
- Strategic push into generics via the Wagner brand and unique position in distributing GPL1 medications and weight loss drugs.
- GPL1 consumption in Australia is growing quickly but remains immature compared to other western countries, positioning CWH as a major beneficiary.
- Initial investment in SIG was at a small-cap level, showcasing the Fund’s strength in identifying opportunities across market capitalizations.
Hyperion Asset Management
30 Apr 2025
$3.02
Summary
- Hyperion Asset Management initiated a position in Sigma Healthcare following its acquisition of Chemist Warehouse Group.
- The merger creates a leading retail pharmacy franchisor and full-line pharmaceutical wholesaler.
- Combined strengths include Sigma’s automated distribution and Chemist Warehouse’s retail expertise.
- The Merged Group supports nearly 900 franchise stores under brands like Chemist Warehouse and Amcal.
- It supplies over 3,500 pharmacy customers with a wide range of products.
- Strong growth prospects are driven by the Chemist Warehouse brand's reputation for value.
- Competitive advantages include a market-leading franchise model and efficient supply chain.
- Founding shareholders of Chemist Warehouse hold 48% ownership in Sigma, ensuring alignment of interests.
Airlie Funds Management
31 Mar 2025
$2.88
Summary
- Chemist Warehouse is gaining traction in Ireland, similar to Aldi and Lidl's disruption in the grocery sector.
- Visited three stores in Dublin; elevated store traffic observed during morning trade.
- Store layouts mimic Australia, featuring high shelves and vibrant price stickers for a theatrical shopping experience.
- Dispensary placement at the back of the store allows focus on front-of-shop items like vitamins and skincare.
- Average pharmacy in Ireland has a 40% gross margin, enabling Chemist Warehouse to offer 20-30% lower prices.
- This pricing strategy drives increased sales volumes, resulting in significant operating leverage.
- Chemist Warehouse is adapting to the local market by stocking more Irish brands while retaining popular Australian brands.
- They are building a warehouse for better inventory management and future e-commerce capabilities.
- Market in Ireland is highly fragmented, with ~60% of pharmacies being single or two-store operators.
- Key competitor Boots has 92 stores and is securing exclusive leases, but Chemist Warehouse is adapting by targeting bulky goods centers.
- Chemist Warehouse currently has 12 stores in Ireland, aiming for 15 by June, with a long-term target of 40-50 stores.
- If successful in Ireland, expansion into the UK is anticipated, where Boots is also a major competitor.
Ten Cap
28 Feb 2025
$2.94
Summary
- Ten Cap continues to hold Sigma Healthcare Ltd due to its robust earnings profile.
- The recent investor presentation reaffirmed Sigma's defensive earnings qualities.
- While the update reiterated previous information from January, it provided additional details on sources of operating leverage.
- Active management of exposure remains a focus for Ten Cap.
Wilson Asset Management
31 Jan 2025
$2.87
Summary
- Sigma Healthcare is a pharmaceutical wholesaler and distributor supplying retail pharmacies.
- Key clients include well-known brands like Amcal and Guardian.
- In January, Sigma Healthcare's $34 billion merger with Chemist Warehouse was approved.
- This merger creates a vertically integrated pharmacy wholesaler and retailer.
- The combined entity will operate almost 1,000 stores.
- Chemist Warehouse reported a 13% increase in unaudited results.
- Wilson Asset Management continues to hold because of the potential for growth and market consolidation.
Ten Cap
31 Jan 2025
$2.87
Summary
- Ten Cap has taken advantage of positive trading data to reduce their position in Sigma (SIG).
- The business demonstrates high quality and defensive earnings.
- There are exciting offshore expansion opportunities ahead.
- Expect continued share price volatility as the market adapts to index inclusion.
- Ten Cap is actively managing their position in response to market conditions.
Cooper Investors
31 Dec 2024
$2.62
Summary
- Cooper Investors benefited from Sigma Healthcare's (SIG) performance during the December quarter.
- The ACCC announced it would not oppose the merger of SIG and Chemist Warehouse on November 7th.
- While initial value latency from the merger has largely been realized, Chemist Warehouse exhibits strong Stalwart characteristics as a high-quality franchise retailer.
- Favorable unit economics contribute to Chemist Warehouse's competitive edge.
- Over the medium term, Chemist Warehouse's 100-year business plan can be replicated globally.
- The company's expansion is ongoing in Ireland, China, and Dubai.
- Compared to ASX Consumer Staples (WES, WOW, COL), Chemist Warehouse shows a superior organic growth profile domestically.
- The merger positions SIG/Chemist Warehouse with a market capitalization larger than Coles (COL).
- This significant market cap may lead to multiple index inclusions, resulting in passive index buying in the coming months.
Airlie Funds Management
31 Dec 2024
$2.62
Summary
- ACCC’s approval of Sigma’s merger with Chemist Warehouse is a key milestone.
- Share price reacted favourably, rising 82% during the quarter following the announcement.
- The final hurdle is the shareholder vote, viewed as a formality at this stage.
- Detailed scheme booklet and other merger-related material have been meticulously scrutinised to enhance understanding of the business.
- Despite the combined group trading on a very elevated earnings multiple, Chemist Warehouse is considered a business that merits such a premium.
- For a comprehensive overview of the Sigma/Chemist Warehouse thesis, refer to Airlie Funds Management's stock story in the September quarterly update.
Milford Asset Management
30 Nov 2024
$2.86
Summary
- Sigma Healthcare has shown a strong performance, rallying 47.4%.
- Milford Asset Management notes the confirmation from ACCC regarding the merger with Chemist Warehouse Group.
- Chemist Warehouse Group holds a dominant competitive position in its niche.
- There is an attractive growth pipeline for Sigma Healthcare both domestically and internationally.
- Growth opportunities are identified in New Zealand, Ireland, and China.
- Milford Asset Management continues to hold Sigma Healthcare due to these positive developments.
Milford Asset Management
31 Oct 2024
$1.96
Summary
- Sigma Pharmaceuticals has shown a positive performance, rallying by 36.5%.
- Growth is supported by an increasing likelihood of a merger with Chemist Warehouse.
- Chemist Warehouse holds a dominant competitive position in its niche.
- There is a strong growth pipeline internationally in markets such as New Zealand, Ireland, and China.
- Milford Asset Management remains confident in the probability of ACCC approval, though it acknowledges some uncertainty.
- The fund continues to manage position sizes to reflect the associated risks.
Airlie Funds Management
30 Sept 2024
$1.44
Summary
- Sigma Healthcare continues to show promise, particularly through its potential merger with Chemist Warehouse.
- Chemist Warehouse experienced a 34% growth in profit before tax in FY24, accelerating to 41% in the second half.
- Airlie Funds Management is attracted to Chemist Warehouse due to its dominant competitive position in the pharmacy niche.
- The company operates on a discount retail model, enabling it to negotiate lower prices from suppliers and pass savings to customers.
- This model results in best-in-class sales per square metre compared to global pharmacy peers.
- Management is founder-led and has significant personal investment in the company.
- Chemist Warehouse has a robust balance sheet and a long growth pipeline, with less than 10% market penetration in Australia.
- By replicating its success in Victoria, Chemist Warehouse could grow its Australian store network by 65%.
- The company is also expanding internationally, with 70 stores across New Zealand, Ireland, and China.
- Expansion requires minimal capital investment, potentially creating significant economic value for shareholders.
- The major risk is the potential block by the ACCC regarding the merger.
- At an average purchase price of $1.10, Airlie Funds Management assessed the risk-reward scenario favorably.
- The recent enforceable undertaking by Chemist Warehouse suggests improved chances of ACCC approval.
- At a current share price of $2.00, Airlie Funds Management has slightly trimmed their position to manage risk.
- Despite the risks, Airlie Funds Management remains optimistic about the long-term opportunity and considers deal completion likely.
Cooper Investors
30 Sept 2024
$1.44
Summary
- Cooper Investors increased their Sigma (SIG) position during the period.
- The merger process with Chemist Warehouse is ongoing.
- Regulatory risks are acknowledged, but Cooper Investors views the ACCC’s initial statement positively.
- There is optimism that Sigma, Chemist Warehouse, and the ACCC can resolve identified concerns.
- Chemist Warehouse is recognized as a high-quality retailer with a strong consumer offering.
- The retailer has favorable unit economics and long-term growth potential.
- ASX100 inclusion is anticipated if the merger proceeds as planned.
Airlie Funds Management
31 Dec 2023
$1.00
Summary
- Airlie Funds Management has established a small position in Sigma Healthcare.
- Chemist Warehouse's strategic move to backdoor Sigma into the pharmaceutical wholesaler is noteworthy.
- Sigma will provide wholesale services to Chemist Warehouse for pharmaceuticals, winning a contract from EBOS.
- The fund manager initiated this position following Sigma's capital raise late in the quarter.
- Airlie Funds Management views Chemist Warehouse as a high-quality operation with significant growth potential.
- Research focused on franchise agreements, pharmacy regulatory environment, and potential ACCC issues.
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Sigma Healthcare Ltd (ASX:SIG)?
Fund managers including Ten Cap, Milford Asset Management, Cooper Investors, Airlie Funds Management, Wilson Asset Management, Hyperion Asset Management, ELM Responsible Investments, Pendal Group and Antares Capital have invested in Sigma Healthcare Ltd (ASX:SIG).
Why do fund managers invest in Sigma Healthcare Ltd?
Fund managers invest in Sigma Healthcare Ltd due to its robust assets and strong earnings profile, particularly after its merger with Chemist Warehouse, which significantly enhances growth prospects. The company benefits from a leading position in Australia’s retail pharmacy sector and a proven business model that excels in cost efficiency. Moreover, the anticipated synergies from their integration, along with international expansion opportunities, provide a favorable risk/reward balance, making Sigma an attractive long-term investment.
What happened to Sigma Healthcare Ltd (ASX:SIG)?
Fund managers are investing in Sigma Healthcare Ltd due to its strong sales momentum, particularly from the Chemist Warehouse acquisition, which has driven significant revenue growth. Recent reports highlight 14.7% like-for-like sales growth and a robust first-quarter performance, aided by the introduction of GLP-1 anti-obesity treatments. The company is also achieving operational efficiencies faster than expected, with synergy benefits projected to reach $100 million annually by year four. Additionally, the shift in consumer behavior towards pharmacy retail over supermarkets, combined with Sigma’s scalable business model and expansion plans in both Australia and New Zealand, supports a favorable long-term growth outlook.
What is the short interest in Sigma Healthcare Ltd (ASX:SIG)?
The short interest in Sigma Healthcare Ltd (ASX:SIG) is 2.21% which makes it the 119th most shorted stock on the ASX. Of the 11.5B shares that Sigma Healthcare Ltd has on issue, 255.4M have been sold short.
What does Sigma Healthcare Ltd (ASX:SIG) do?
Sigma Healthcare Ltd. engages in the manufacture and distribution of pharmaceutical products through pharmacy, grocery channels, and private labels. The firm's activities include wholesale distribution of pharmaceutical goods and medical consumables to community pharmacies, including the provision of retail support services to the branded network of pharmacy members, dose administration aid services, technology and data analytics solutions to the customers. The company was founded in 1912 and is headquartered in Clayton, Australia.